Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 2,421–2,430 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 2421

    Medicine slug
    elexacaftor-ivacaftor-tezacaftor
    Medicine name
    Elexacaftor, Ivacaftor, Tezacaftor
    Enzyme or transporter
    OCT2
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:f354423a-85c2-41c3-a9db-0f3aee135d8d (opens source in a new tab)

      Elexacaftor, Ivacaftor, Tezacaftor label

      Version not recorded · Effective date not recorded

      Tezacaftor has a low potential to inhibit BCRP, OCT2, OAT1, or OAT3.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:f354423a-85c2-41c3-a9db-0f3aee135d8d (opens source in a new tab)

      Elexacaftor, Ivacaftor, Tezacaftor label

      Version not recorded · Effective date not recorded

      Tezacaftor has a low potential to inhibit BCRP, OCT2, OAT1, or OAT3.
    3. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:f354423a-85c2-41c3-a9db-0f3aee135d8d (opens source in a new tab)

      Elexacaftor, Ivacaftor, Tezacaftor label

      Version not recorded · Effective date not recorded

      Ivacaftor is not an inhibitor of the transporters OCT1, OCT2, OAT1, or OAT3.
    4. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:f354423a-85c2-41c3-a9db-0f3aee135d8d (opens source in a new tab)

      Elexacaftor, Ivacaftor, Tezacaftor label

      Version not recorded · Effective date not recorded

      Ivacaftor is not an inhibitor of the transporters OCT1, OCT2, OAT1, or OAT3.

  2. Projected row 2422

    Medicine slug
    elexacaftor-ivacaftor-tezacaftor
    Medicine name
    Elexacaftor, Ivacaftor, Tezacaftor
    Enzyme or transporter
    P-GP
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:f354423a-85c2-41c3-a9db-0f3aee135d8d (opens source in a new tab)

      Elexacaftor, Ivacaftor, Tezacaftor label

      Version not recorded · Effective date not recorded

      Based on in vitro results, elexacaftor and tezacaftor have a low potential to inhibit the transporter P-gp, while ivacaftor has the potential to inhibit P-gp.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:f354423a-85c2-41c3-a9db-0f3aee135d8d (opens source in a new tab)

      Elexacaftor, Ivacaftor, Tezacaftor label

      Version not recorded · Effective date not recorded

      Based on in vitro results, elexacaftor and tezacaftor have a low potential to inhibit the transporter P-gp, while ivacaftor has the potential to inhibit P-gp.

  3. Projected row 2423

    Medicine slug
    elexacaftor-ivacaftor-tezacaftor
    Medicine name
    Elexacaftor, Ivacaftor, Tezacaftor
    Enzyme or transporter
    P-GP
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:f354423a-85c2-41c3-a9db-0f3aee135d8d (opens source in a new tab)

      Elexacaftor, Ivacaftor, Tezacaftor label

      Version not recorded · Effective date not recorded

      Co-administration of tezacaftor/ivacaftor with digoxin, a sensitive P-gp substrate, increased digoxin exposure by 1.3-fold in a clinical study.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:f354423a-85c2-41c3-a9db-0f3aee135d8d (opens source in a new tab)

      Elexacaftor, Ivacaftor, Tezacaftor label

      Version not recorded · Effective date not recorded

      Co-administration of tezacaftor/ivacaftor with digoxin, a sensitive P-gp substrate, increased digoxin exposure by 1.3-fold in a clinical study.
    3. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:f354423a-85c2-41c3-a9db-0f3aee135d8d (opens source in a new tab)

      Elexacaftor, Ivacaftor, Tezacaftor label

      Version not recorded · Effective date not recorded

      In vitro studies showed that elexacaftor and tezacaftor are substrates for the efflux transporter P-gp, but ivacaftor is not.
    4. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:f354423a-85c2-41c3-a9db-0f3aee135d8d (opens source in a new tab)

      Elexacaftor, Ivacaftor, Tezacaftor label

      Version not recorded · Effective date not recorded

      In vitro studies showed that elexacaftor and tezacaftor are substrates for the efflux transporter P-gp, but ivacaftor is not.

  4. Projected row 2424

    Medicine slug
    eliglustat
    Medicine name
    Eliglustat
    Enzyme or transporter
    CYP2D6
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    21
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      12.3 Pharmacokinetics Absorption The oral bioavailability of eliglustat was less than 5% in CYP2D6 EMs following a single 84 mg dose of CERDELGA.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      In CYP2D6 EMs, the eliglustat pharmacokinetics is time-dependent and the systemic exposure increases in a more than dose-proportional manner over the dose range of 42 to 294 mg (0.5 to 3.5 times the recommended dosage).
    3. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      The pharmacokinetics of eliglustat in CYP2D6 PMs is expected to be linear and time-independent.
    4. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Table 7: Pharmacokinetic Parameters for Eliglustat following Multiple Doses of 84 mg CERDELGA Twice Daily Parameter CYP2D6 Metabolizer Status EMs (n=96) IMs (n=1) PMs 84 mg twice daily is not the recommended dosage in PMs [see Dosage and Administration (2.2) ] .
    5. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Elimination Eliglustat terminal elimination half-life was approximately 6.5 hours in CYP2D6 EMs, and 8.9 hours in PMs.
    6. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Metabolism CERDELGA is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4.
    7. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Patients with renal impairment Eliglustat pharmacokinetics was similar in CYP2D6 EMs with severe renal impairment and healthy CYP2D6 EMs.
    8. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Patients with hepatic impairment Table 8 describes the effect of mild and moderate hepatic impairment on the pharmacokinetics of eliglustat in CYP2D6 EMs compared to EMs with normal hepatic function following a single 84 mg dose.
    9. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      The effect of hepatic impairment is highly variable with the coefficients of variation (CVs%) of 135% and 110% for C max and 171% and 121% for AUC in CYP2D6 EMs with mild and moderate hepatic impairment, respectively.
    10. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Table 8: Effect of Hepatic Impairment on Eliglustat Pharmacokinetics following a Single Dose of 84 mg CERDELGA in CYP2D6 EMs Mild Hepatic Impairment (n=6) Moderate Hepatic Impairment (n=7) C max ↑ 1.2-fold ↑ 2.8-fold AUC ↑ 1.2-fold ↑ 5.2-fold Steady-state pharmacokinetics of eliglustat in CYP2D6 IMs and PMs with mild and moderate hepatic impairment is unknown.
    11. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      The effect of severe hepatic impairment in subjects with any CYP2D6 phenotype is unknown [see Use in Specific Populations (8.7) ] .
    12. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      In CYP2D6 EMs, the eliglustat pharmacokinetics is time-dependent and the systemic exposure increases in a more than dose-proportional manner over the dose range of 42 to 294 mg (0.5 to 3.5 times the recommended dosage).
    13. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      The pharmacokinetics of eliglustat in CYP2D6 PMs is expected to be linear and time-independent.
    14. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Table 7: Pharmacokinetic Parameters for Eliglustat following Multiple Doses of 84 mg CERDELGA Twice Daily Parameter CYP2D6 Metabolizer Status EMs (n=96) IMs (n=1) PMs 84 mg twice daily is not the recommended dosage in PMs [see Dosage and Administration (2.2) ] .
    15. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Elimination Eliglustat terminal elimination half-life was approximately 6.5 hours in CYP2D6 EMs, and 8.9 hours in PMs.
    16. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Metabolism CERDELGA is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4.
    17. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Patients with renal impairment Eliglustat pharmacokinetics was similar in CYP2D6 EMs with severe renal impairment and healthy CYP2D6 EMs.
    18. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Patients with hepatic impairment Table 8 describes the effect of mild and moderate hepatic impairment on the pharmacokinetics of eliglustat in CYP2D6 EMs compared to EMs with normal hepatic function following a single 84 mg dose.
    19. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      The effect of hepatic impairment is highly variable with the coefficients of variation (CVs%) of 135% and 110% for C max and 171% and 121% for AUC in CYP2D6 EMs with mild and moderate hepatic impairment, respectively.
    20. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Table 8: Effect of Hepatic Impairment on Eliglustat Pharmacokinetics following a Single Dose of 84 mg CERDELGA in CYP2D6 EMs Mild Hepatic Impairment (n=6) Moderate Hepatic Impairment (n=7) C max ↑ 1.2-fold ↑ 2.8-fold AUC ↑ 1.2-fold ↑ 5.2-fold Steady-state pharmacokinetics of eliglustat in CYP2D6 IMs and PMs with mild and moderate hepatic impairment is unknown.
    21. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      The effect of severe hepatic impairment in subjects with any CYP2D6 phenotype is unknown [see Use in Specific Populations (8.7) ] .

  5. Projected row 2425

    Medicine slug
    eliglustat
    Medicine name
    Eliglustat
    Enzyme or transporter
    CYP2D6
    Role
    SUBSTRATE
    Asserted sentences
    4
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Effect of CERDELGA on other drugs CYP2D6 substrates Following multiple doses of CERDELGA 127 mg twice daily (1.5 times the recommended dosage), metoprolol (a CYP2D6 substrate) mean C max and AUC increased by 1.7-fold and 2.3-fold in CYP2D6 EMs, respectively, and by 1.2-fold and 1.6-fold in IMs, respectively [see Drug Interactions (7.2) ] .
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      P-gp substrates Following multiple doses of CERDELGA 127 mg twice daily (1.5 times the recommended dosage) in CYP2D6 EMs and IMs, or 84 mg twice daily in PMs, digoxin (a P-gp substrate) mean C max increased by 1.7-fold and AUC increased by 1.5-fold [see Drug Interactions (7.2) ] .
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Effect of CERDELGA on other drugs CYP2D6 substrates Following multiple doses of CERDELGA 127 mg twice daily (1.5 times the recommended dosage), metoprolol (a CYP2D6 substrate) mean C max and AUC increased by 1.7-fold and 2.3-fold in CYP2D6 EMs, respectively, and by 1.2-fold and 1.6-fold in IMs, respectively [see Drug Interactions (7.2) ] .
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      P-gp substrates Following multiple doses of CERDELGA 127 mg twice daily (1.5 times the recommended dosage) in CYP2D6 EMs and IMs, or 84 mg twice daily in PMs, digoxin (a P-gp substrate) mean C max increased by 1.7-fold and AUC increased by 1.5-fold [see Drug Interactions (7.2) ] .

  6. Projected row 2426

    Medicine slug
    eliglustat
    Medicine name
    Eliglustat
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Metabolism CERDELGA is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      Metabolism CERDELGA is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4.

  7. Projected row 2427

    Medicine slug
    eliglustat
    Medicine name
    Eliglustat
    Enzyme or transporter
    P-GLYCOPROTEIN
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      In vitro , eliglustat is a substrate of P-glycoprotein (P-gp).
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      In vitro , eliglustat is a substrate of P-glycoprotein (P-gp).

  8. Projected row 2428

    Medicine slug
    eliglustat
    Medicine name
    Eliglustat
    Enzyme or transporter
    P-GP
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      The effect of P-gp inhibitors on eliglustat pharmacokinetics is unknown.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      The effect of P-gp inhibitors on eliglustat pharmacokinetics is unknown.

  9. Projected row 2429

    Medicine slug
    eliglustat
    Medicine name
    Eliglustat
    Enzyme or transporter
    P-GP
    Role
    SUBSTRATE
    Asserted sentences
    4
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      In vitro , eliglustat is a substrate of P-glycoprotein (P-gp).
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      P-gp substrates Following multiple doses of CERDELGA 127 mg twice daily (1.5 times the recommended dosage) in CYP2D6 EMs and IMs, or 84 mg twice daily in PMs, digoxin (a P-gp substrate) mean C max increased by 1.7-fold and AUC increased by 1.5-fold [see Drug Interactions (7.2) ] .
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      In vitro , eliglustat is a substrate of P-glycoprotein (P-gp).
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:819f828a-b888-4e46-83fc-94d774a28a83 (opens source in a new tab)

      Eliglustat label

      Version not recorded · Effective date not recorded

      P-gp substrates Following multiple doses of CERDELGA 127 mg twice daily (1.5 times the recommended dosage) in CYP2D6 EMs and IMs, or 84 mg twice daily in PMs, digoxin (a P-gp substrate) mean C max increased by 1.7-fold and AUC increased by 1.5-fold [see Drug Interactions (7.2) ] .

  10. Projected row 2430

    Medicine slug
    elinzanetant
    Medicine name
    Elinzanetant
    Enzyme or transporter
    BCRP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    4
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:f42884ff-7dff-419c-8a0c-affe2ed73818 (opens source in a new tab)

      Elinzanetant label

      Version not recorded · Effective date not recorded

      No clinically significant differences in the pharmacokinetics of the following oral drugs were observed when used concomitantly with elinzanetant: tamoxifen (substrate of CYP2D6, CYP3A4 and P-gp) and rosuvastatin (substrate of BCRP, OATP1B1/OATP1B3, and OAT3).
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:f42884ff-7dff-419c-8a0c-affe2ed73818 (opens source in a new tab)

      Elinzanetant label

      Version not recorded · Effective date not recorded

      Elinzanetant and its metabolites M18/21, M27, and M30/M34 inhibited P-gp, BCRP, and BSEP in vitro but did not inhibit OAT1, OAT3, OCT1, OCT2, MATE2-K, or MRP2.
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:f42884ff-7dff-419c-8a0c-affe2ed73818 (opens source in a new tab)

      Elinzanetant label

      Version not recorded · Effective date not recorded

      No clinically significant differences in the pharmacokinetics of the following oral drugs were observed when used concomitantly with elinzanetant: tamoxifen (substrate of CYP2D6, CYP3A4 and P-gp) and rosuvastatin (substrate of BCRP, OATP1B1/OATP1B3, and OAT3).
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:f42884ff-7dff-419c-8a0c-affe2ed73818 (opens source in a new tab)

      Elinzanetant label

      Version not recorded · Effective date not recorded

      Elinzanetant and its metabolites M18/21, M27, and M30/M34 inhibited P-gp, BCRP, and BSEP in vitro but did not inhibit OAT1, OAT3, OCT1, OCT2, MATE2-K, or MRP2.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=2420

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy